People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel mechanisms of action.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Earlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...